Drugs / Leukocyte-poor PRP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02923700 | Sep 2016 → Sep 2017 | osteoarthritis | Rizzoli Orthopaedic Institute | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leukocyte-poor PRP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02923700 ↗ |
| Known as | LP-PRP | “PURPOSE: To compare the safety and effectiveness of leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP) for the treatment of knee OA.” PMID 35103547 ↗ Feb 2022 |